German 3D printing innovator xolo has entered into a co-branding agreement with Rousselot, a leading collagen and gelatin brand under Darling Ingredients. This collaboration aims to integrate Rousselot’s X-Pure Gelatin Methacrylate (GelMA) solution into xolo’s bioinks for volumetric 3D printers, potentially bridging the gap between research and clinical applications in bioprinting.
By combining xolo’s Xolography 3D printing technology—which is capable of producing complex cellular structures with speed and precision—and Rousselot’s X-Pure GelMA, known for its consistent purity and ability to support cell growth, the partnership seeks to provide stable and reproducible printing results. This synergy is expected to accelerate medical research and advance biomedical innovation by offering high-quality, ready-to-use bioinks that complement xolo’s advanced printing technology.
Earlier this year, xolo secured €8 million in funding, with HZG Group among the investors, and subsequently launched its Xube² 3D Volumetric Printing system. The collaboration with Rousselot represents a strategic move to meet the growing demand for reliable bioprinting solutions that enable researchers to focus on their work without concerns about quality issues.
About xolo
xolo is a German company specializing in volumetric 3D printing technology, particularly in the field of bioprinting. With its innovative Xolography technology and the recent launch of the Xube² 3D Volumetric Printing system, xolo aims to push the boundaries of biomedical innovation by providing advanced printing solutions that facilitate the creation of complex cellular structures.
About Rousselot
Rousselot, a brand of Darling Ingredients, is a global leader in the production of collagen and gelatin solutions. With its X-Pure range, including Gelatin Methacrylate (GelMA), Rousselot offers high-quality, GMP-grade products designed to support medical research and translational applications. The company is committed to advancing biomedical innovation through partnerships and the provision of reliable, consistent biomaterials.
The Business of Biofabrication 
Leave a comment